(Q38736457)

6 September 2017

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models (English)

1 reference

6 September 2017

Brandon J Aubrey

37

0 references

Pawel Dokurno

Pawel Dokurno

23

0 references

Marco J Herold

Marco J Herold

39

0 references

Andrew W. Roberts

Andrew W Roberts

48

0 references

Andreas Strasser

Andreas Strasser

51

0 references

Catherine McBride-Chang

40

Catherine Chang

1 reference

6 September 2017

49

David C S Huang

1 reference

6 September 2017

38

Margs S Brennan

1 reference

6 September 2017

8

Gemma L Kelly

1 reference

6 September 2017

9

Jia-Nan Gong

1 reference

6 September 2017

András Kotschy

1

1 reference

6 September 2017

Zoltán Szlavik

2

1 reference

6 September 2017

James Murray

3

1 reference

6 September 2017

James Davidson

4

1 reference

6 September 2017

Ana Leticia Maragno

5

1 reference

6 September 2017

Gaëtane Le Toumelin-Braizat

6

1 reference

6 September 2017

Maïa Chanrion

7

1 reference

6 September 2017

Donia M Moujalled

10

1 reference

6 September 2017

Alain Bruno

11

1 reference

6 September 2017

Márton Csekei

12

1 reference

6 September 2017

Attila Paczal

13

1 reference

6 September 2017

Zoltán B Szabo

14

1 reference

6 September 2017

Szabolcs Sipos

15

1 reference

6 September 2017

Gábor Radics

16

1 reference

6 September 2017

Agnes Proszenyak

17

1 reference

6 September 2017

Balázs Balint

18

1 reference

6 September 2017

Levente Ondi

19

1 reference

6 September 2017

Gábor Blasko

20

1 reference

6 September 2017

Alan Robertson

21

1 reference

6 September 2017

Allan Surgenor

22

1 reference

6 September 2017

Ijen Chen

24

1 reference

6 September 2017

Natalia Matassova

25

1 reference

6 September 2017

Julia Smith

26

1 reference

6 September 2017

Christopher Pedder

27

1 reference

6 September 2017

Christopher Graham

28

1 reference

6 September 2017

Aurélie Studeny

29

1 reference

6 September 2017

Gaëlle Lysiak-Auvity

30

1 reference

6 September 2017

Anne-Marie Girard

31

1 reference

6 September 2017

Fabienne Gravé

32

1 reference

6 September 2017

David Segal

33

1 reference

6 September 2017

Chris D Riffkin

34

1 reference

6 September 2017

Giovanna Pomilio

35

1 reference

6 September 2017

Laura C A Galbraith

36

1 reference

6 September 2017

Ghislaine Guasconi

41

1 reference

6 September 2017

Nicolas Cauquil

42

1 reference

6 September 2017

Fabien Melchiore

43

1 reference

6 September 2017

Nolwen Guigal-Stephan

44

1 reference

6 September 2017

Brian Lockhart

45

1 reference

6 September 2017

Frédéric Colland

46

1 reference

6 September 2017

John A Hickman

47

1 reference

6 September 2017

Andrew H Wei

50

1 reference

6 September 2017

Guillaume Lessene

52

1 reference

6 September 2017

Olivier Geneste

53

1 reference

6 September 2017

language of work or name

English

0 references

publication date

19 October 2016

1 reference

6 September 2017

1 reference

6 September 2017

538

1 reference

6 September 2017

477-482

1 reference

6 September 2017

7626

1 reference

https://scigraph.springernature.com/pub.10.1038/nature19830

6 September 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Decoding and unlocking the BCL-2 dependency of cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

The landscape of somatic copy-number alteration across human cancers

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Mcl-1 is a potential therapeutic target in multiple types of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

BCL-2 family antagonists for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

A synergistic approach to protein crystallization: combination of a fixed-arm carrier with surface entropy reduction.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

https://api.crossref.org/works/10.1038%2FNATURE19830

1 reference

7 January 2021

MOLREP: an Automated Program for Molecular Replacement

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Refinement of macromolecular structures by the maximum-likelihood method

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FNATURE19830

7 January 2021

Identifiers

DOI

10.1038/NATURE19830

1 reference

release_wqfgih4cmbd2fd7umiuhj4xpzu

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wqfgih4cmbd2fd7umiuhj4xpzu

24 November 2022

mapped directly with Wikidata item

1 reference